Pfizer enters takeover discussions with AstraZeneca - WSJ

Fri May 2, 2014 9:37am IST

A sale sign hangs near an AstraZeneca site in Macclesfield, central England April 28, 2014.  U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid battle for Britain's AstraZeneca Plc after having a two bids rejected, as deal-making grips the healthcare industry. Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover.  REUTERS/Darren Staples   (BRITAIN - Tags: BUSINESS HEALTH) - RTR3MXHF

A sale sign hangs near an AstraZeneca site in Macclesfield, central England April 28, 2014. U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid battle for Britain's AstraZeneca Plc after having a two bids rejected, as deal-making grips the healthcare industry. Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover.

Credit: Reuters/Darren Staples (BRITAIN - Tags: BUSINESS HEALTH) - RTR3MXHF

Related Topics

Stocks

   

(Reuters) - Pfizer Inc and Plc have resumed talks about a trans-Atlantic merger of the two drug giants after Pfizer sweetened the terms of an earlier takeover offer for its British rival, the Wall Street Journal reported, citing people familiar with the matter.

The renewed discussions suggest that the two sides might be getting closer to striking a friendly deal, but there is no guarantee the talks will go anywhere, the Journal said, adding that the terms of the informal offer from Pfizer couldn't be learned.

Bloomberg reported earlier in the day that Pfizer may sweeten its offer for AstraZeneca to more than 63 billion pounds, or $106 billion, and raise the cash portion of the deal, to kickstart negotiations.

Citing people with knowledge of the matter, the Bloomberg report said a new bid may value AstraZeneca at more than 50 pounds ($84.47) per share and could come as early as next week.

Pfizer disclosed earlier this week that it had twice approached AstraZeneca about a takeover, only to be rebuffed in both cases.

Pfizer and AstraZeneca declined to comment on the Bloomberg report.

Since Pfizer went public with its approach to AstraZeneca, investors and analysts have been expecting the largest U.S. drugmaker would come back with more than its initial offer worth 58.8 billion pounds ($98.9 billion) and increase the cash component. Under British takeover rules, Pfizer has until May 26 to announce its intent to make an offer for AstraZeneca, or walk away.

When Astra turned down the Pfizer offer, it did not simply say that the bid significantly undervalued the company; it put a "very" in front of it, noted John Boris, an analyst with SunTrust Robinson Humphrey.

"They're basically saying 'come back to me with a materially higher offer,'" said Boris. He predicted that Pfizer would raise the offer to about $110 billion, or $87 a share.

A purchase of AstraZeneca would not only bolster Pfizer's pipeline of cancer drugs in development, but allow it to redomicile in Britain to take advantage of significantly lower tax rates there, and to use tens of billions of dollars it has overseas without having to pay high taxes for bringing the cash back to the United States.

Pfizer shares closed 0.4 percent lower at $31.15 on the New York Stock Exchange on Thursday.

(Reporting by Bill Berkrot and Ransdell Pierson and Supriya Kurane in Bangalore; Editing by Richard Chang and Matt Driskill)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Drug Pricing

REUTERS SHOWCASE

Modi Speaks

Modi Speaks

PM Modi says al Qaeda will fail in India - CNN.  Full Article 

Price Cap

Price Cap

India caps prices of 36 more drugs to improve access - govt official.  Full Article 

India-US Diplomacy

India-US Diplomacy

Obama to nominate Indian-American Richard Verma as India ambassador - congressional source.  Full Article 

Importing Rice

Importing Rice

Top rice exporter India importing over 100,000 T on temporary supply squeeze.  Full Article 

GSK Fined

GSK Fined

China hands drugmaker GSK record $489 mln fine, sentences executives.  Full Article 

HMT in Demand

HMT in Demand

Fans rush to HMT as watchmaker marks time.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage